A Comparative Perspective Study between Intrathecal Midazolam & Nalbuphine as an adjuvant with Hyperbaric Bupivacaine for Post-Operative Analgesia in Total Abdominal Hysterectomy

Stuti Dubey a*, Sanjot Ninave a, Aruna Chandak a, Vijay Chandak a, Neeta Verma a and Nikhil Bhalerao a†

a Department of Anaesthesia, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Meghe, Wardha, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34695

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/80207

Received 15 October 2021
Accepted 20 December 2021
Published 23 December 2021

ABSTRACT

Background: Subarachnoid block is the preferred form of regional anesthesia for obstetric surgeries. Local anesthetic agents alone are insufficient in providing adequate postoperative analgesia, which is an essential factor for the patients & is the sole essence of anesthesia. Adding adjuvant will result in better quality, the efficacy of SAB & will prolong analgesia postoperatively. Due to minimal hemodynamic & respiratory complications, Nalbuphine, an opioid, can be favored as an adjuvant to subarachnoid block. The addition of Nalbuphine in limiting doses to Hyperbaric Bupivacaine offers improved block quality & adequate pre & post-operative analgesia. Midazolam, an imidazobenzodiazepine given intrathecally, raises the threshold of pain; it also has hypnotic, anticonvulsant, muscle relaxant & amnesic effects of other benzodiazepines.

Objectives: Primarily to compare the duration of pain relief in the postoperative period between administration of Intrathecal Nalbuphine (1mg) & Midazolam(2.5mg) (Timing of 1st rescue
analgesia). Secondarily to compare the onset of action & duration of motor & sensory block (Modified Bromage Scale), Effect on Hemodynamic Parameters, 24 hours requirement of analgesic (No. of Injection Paracetamol 15-20mg/kg ), Degree of sedation(Modified Ramsay Sedation Scale) & After-effects(PONV, Pruritis, Shivering & Retention of urine).

**Methodology:** The study type will be a Comparative Prospective Study on 60 ASA 1 & 2 females in the age group 35-75 years, planned for total abdominal hysterectomy will be separated in two equivalent Group M (n=30) & Group N (n=30). Group M will receive combination Midazolam preservative-free 0.5 ml (2.5 mg) with 0.5% Hyperbaric Bupivacaine 2.5 ml(12.5 mg), & Group N will receive combination Nalbuphine 1 ml (1 mg) with Hyperbaric Bupivacaine (0.5%) 2.5 ml (12.5mg) by Intrathecal Route. Analgesia duration in the postoperative period, the onset of action & duration of motor & sensory block, effect on hemodynamic parameters, 24 hours analgesics requirement, degree of sedation, after-effects, if any, will be studied & compared.

**Conclusion:** Expected to prove the hypothesis that adding which of the following adjuvant 1mg Nalbuphine or 2.5mg Midazolam with 0.5% Hyperbaric Bupivacaine intrathecally given in SAB prolongs the postoperative analgesia duration more as compared to other.

**Keywords:** Subarachnoid block; total abdominal hysterectomy; intrathecal; nalbuphine; post-operative analgesia; midazolam.

### 1. INTRODUCTION

Subarachnoid block was introduced about a hundred years ago & is still the most popular regional anesthesia approach. But, the local anesthetic drugs (whether isobaric or hyperbaric) used for subarachnoid block do not prolong postoperative pain relief. Anaesthesiologists face this struggle as they oversee peri & post-operative pain control [1]. Excessively soaring regional blocks & toxicity due to local anesthetics are the most common reasons for deaths linked to regional blocks; therefore, decreasing dosage of local anesthetics, adding adjuvants, usage of latest methodology to circumvent inordinate blocks, & superior tackling of local anesthetic toxicity are the novel targets for reducing death rate linked to regional anesthesia [2].

The subarachnoid block is a preferred technique of anesthesia as it is easy to carry out, the outset of action is rapid, better relaxation of muscle & effectual. Additionally, reduced recovery time, quick return of patient’s average oral intake & safety are its added advantages. Analgesia in the postoperative phase is essential to provide comfort & reinstatement of functions effectively; it is one of the primary concerns of all patients [3,4]. Though subarachnoid block is relatively safe, its duration of action is short. To overcome this snag, various adjuvants are being added per usual. Subarachnoid block with Hyperbaric Bupivacaine 0.5 Percent, along with adjuvants, is consistently administered for lower abdomen surgeries.[5] Numerous drugs were recognized to be used as adjuvants such as Opioids, Adrenaline, Neostigmine, Midazolam, Ketamine, α-2 agonists (Clonidine, Dexmeditomidine) for lengthening of local anesthetic analgesia & action in the postoperative phase [6,7], but drugs have constraints & their adverse effects [6].

**Nalbuphine,** an opioid, has mixed kappa-agonist & mu-antagonist properties. It acts by competitively displacing other mu-agonists from the receptor site (mu-antagonism). Also, its binding to kappa-receptors produces an agonist effect. Due to this mixed pattern of agonism & antagonism, Nalbuphine is a mixed kappa-agonist-mu-antagonist. It has minimal respiratory depression, in contrast to other opioid analgesics acting centrally because it has mixed partial k-receptor agonist &μ-receptor antagonist activity [8,9].

**Midazolam** is a water-soluble imidazobenzodiazepine derivative. Midazolam is similar to other benzodiazepines in binding extensively to plasma proteins. Midazolam has hypnotic, anticonvulsant, muscle relaxation & amnesic effects of other benzodiazeprines [10,11].

#### 1.1 Research Question

Which is more effective among Midazolam 2.5 mg & Nalbuphine 1 mg when used as an Intrathecal Adjuvant to Hyperbaric Bupivacaine in providing analgesia in the post-operative phase?
1.2 Rationale
Numerous studies have been conducted about the individual strength of both drugs. We want to compare which adjuvant is better when administered intrathecally along with Hyperbaric Bupivacaine {0.5%} 2.5 ml (12.5mg). Hence the motive of the study.

1.3 Aim
The study aims to compare the Efficacy of midazolam & nalbuphine when they are added as an Adjuvant with Hyperbaric Bupivacaine (0.5%) intrathecally in patients planned for Total Abdominal Hysterectomy.

1.4 Objectives
1.4.1 Primary
To compare postoperative analgesia duration between midazolam (2.5 mg) & nalbuphine (1 mg) dose intrathecally given along with 0.5% hyperbaric bupivacaine.

1.4.2 Secondary
Comparison of 1) The onset of action & duration of motor & sensory block.
2) The effect on hemodynamic parameters.
3) 24-hour requirement of analgesic(Paracetamol 15-20 mg/kg)
4) Degree of sedation.
5) After-effects(PONV, pruritus, shivering, retention of urine & Any Other)

2. MATERIAL AND METHODS

2.1 Study Design
1. Study Period: 2 years (2020-2022)
2. Study Area: Department of Anaesthesiology JNMC & AVBRH.
3. Research Design: Comparative Prospective Study
4. Study Population: Female Patients 35-75 years of age

2.2 Inclusion Criteria
- Women in the 35-75 age range.
- TAH under spinal anesthesia.
- Surgical duration 2 hours
- American society of anaesthesiologist grade 1 & 2.
- Mallampati classification 1 & 2.

2.3 Exclusion Criteria
- Patient not willing to participate in the study
- American society of anaesthesiologist grade 3 & 4.
- SAB injection site infection.
- Patients with Neuromuscular disorders.
- Patients with bleeding diathesis or on anticoagulant therapy
- Patient allergic to local anesthetic, midazolam & nalbuphine

2.4 Sampling Size and Technique
After approval of the Institution’s Ethics Committee, a Comparative & Prospective study will be done on Sixty patients fulfilling all the Inclusion Criteria.

Patients for the study will be randomly allocated into two groups:
- Group M (n=30): Midazolam with Bupivacaine
- Group N(n=30): Nalbuphine with Bupivacaine

Sample Size formulae used are as follows:

\[ n = \frac{Z_\alpha^2 + Z_\beta^2}{\sigma_1^2 + \sigma_2^2/k} \]

where,
- \( Z_\alpha \) - level of significance at 5%  (95% Confidence Interval) = 1.96
- \( Z_\beta \) - Power of Test = 80% = 0.84
- \( \sigma_1 \) = for Group N, the SD of sensory blockade onset (1.05)
- \( \sigma_2 \) = for Group M, the SD of sensory blockade onset (0.44)
- \( \Delta = 3.04 - 1.95 = 0.61 \) & \( k = 1 \)

\[ n = \frac{(1.96 + 0.84)^2 [1.052 + 0.442/1]}{0.612} \]

\[ = 27.30 \]
\[ n = 30 \text{ patients needed in each group considering dropouts} \]

Refer—determination of the sample size by VK Chandra, NTI Bulletin, 2006, 42/3 & 4, 55-62.

2.5 Methodology

a) Pre-Operative Assessment

1. Patients will be examined for pre-operative assessment a day before surgery for final fitness.
2. Patient details, history of presenting illness, airway assessment, spine examination, nutritional status, detailed general & systemic examination, preoperative blood & other lab investigations of the patient will be noted.
3. Patients will be kept NBM Overnight & pre-medicated using 150 mg of ranitidine, 0.5mg of alprazolam on the eve of surgery.
4. Women fulfilling the inclusion criteria will be informed & explained about the type and motive of the study & consent will be taken in writing.
5. Patients will be randomly separated into 2 Groups—group M, group N by Slips in the Box Method. The patient & the Anaesthesiologist (the outcome’s assessor), who will record the perioperative data, will be blinded to the study drug (Double-Blind Study).

b) INTRA-OPERATIVE

1. Upon reaching OT, multi-para monitors will be connected, e.g., nip monitor, electrocardiogram & Spo2 monitor. Baseline values will be recorded
2. An i.v access will be established with an 18 gauge IV cannula. 10ml/kg of RL will be used to preload.
3. Premedication with injection ondansetron 75-100 µ/kg iv shall be done 10 minutes before the SAB procedure.
4. SAB will be performed at intervertebral space L3-L4 with 25G Quincke needle using the median approach in the left lateral or sitting position following all aseptic measures. The drug will be injected after clear, free-flowing cerebrospinal fluid (CSF) is observed.

Following the procedure patient shall be quickly shifted to a prone position. Supplemental oxygen will be given using Hudson’s mask at 4 L/min.

5. Parameters to be recorded are:
   i) onset of sensorimotor block
   ii) time is taken & max. Level of sensory block attained.
   iii) two-segment regression time of Sensory Block.
   iv) sedation level
   v) postop assessment of pain by VAS.
   vi) timing for 1st rescue analgesia.
   vii) any harmful effects.

An unsharp tipped needle shall be used to check sensory block (pinprick technique) every 2 minutes till a level of surgical anesthesia is attained at T10 dermatome [4]. Assessment of quality of motor block shall be done using modified Bromage scale.

c) BLOCK EVALUATION

Sensory Block

1) Sensory Blockade will be assessed by Pin Prick Technique using unsharp tipped needle, on mid-clavicular line, every min till block at T6 dermatome is attained

2) After that, the Sensory Block will be examined every 2 minutes until the Maximum Sensory Blockade is achieved.

| Group | Drug Given | Total Volume |
|-------|------------|-------------|
| M     | Bupivacaine (H) 2.5ml (12.5mg) of 0.5% + Midazolam 0.5ml (2.5mg) | 3ml |
| N     | Bupivacaine (H) 2.5ml (12.5mg) of 0.5% + Nalbuphine 0.1ml (1mg) normal saline 0.9 ml | 3ml |
Table 2. Grades of sensory blockade

| Grade 0 | Sharp Pain |
|---------|------------|
| Grade 1 | Analgesia, Dull Sensations |
| Grade 2 | Anesthesia, No Sensations |

Table 3. List of motor block

| 0 | No Motor Blockade |
|---|------------------|
| 1 | Inability to raise extended leg; able to move knees & feet |
| 2 | Inability to raise extended leg & move knees; able to move feet |
| 3 | Complete motor block of the limb |

2.6 Sensory Block-Onset and Duration

- Onset is the period between anesthesia injection and sensory block at T10 dermatome.
- Duration - (assessed by two-segment regression) is the period between injection of anesthesia and the decrease of maximum sensory block level by two segments.

2.7 Motor Block

Assessment of the quality of motor blocks will be carried out using a modified Bromage scale.

- Monitoring hemodynamic parameters – every 2 mins for initial 10 mins, every 5 mins for the next 30 mins & finally every 15 mins until the surgery is completed.
- If heart rate reduces to 20 percent below baseline, injection glycopyrrolate will be administered & if the blood pressure falls 20 percent below the baseline, injection mephentermine will be administered.

Side-effects observed following injection of the drug under study shall be recorded and managed.

- I.v fluids will be given, keeping in mind the patient’s weight & fluid loss intraoperatively.
- Intraoperatively, side-effects e.g. nausea, vomiting, pruritis & shivering will be noted. Inj. ondansetron 4 mg i.v to treat nausea & vomiting, injection tramadol 50 mg i.v for shivering, & injection hydrocort 100 mg i.v & injection pheniramine 25 mg i.v for allergic reactions & pruritis.
- Patient will be shifted to the postoperative ward after surgery is completed. Monitoring, every half an hour for initial six hrs, will be done. Later daily monitoring will be done. If the patient shows a VAS score of 4 or more, injection paracetamol 15-20 mg/kg i.v shall be administered as rescue analgesia.

2.7 Visual Analog Scale

- VAS will be described to the patient preoperatively.

Fig. 1. Numeric rating scale
Table 4. VAS Numeric Pain Distress Scale

| Score | Pain   |
|-------|--------|
| 0-2   | Absent |
| 2-4   | Mild   |
| 4-6   | Moderate |
| 6-8   | Severe |
| 8-10  | Unbearable |

Table 5. Modified ramsey sedation score

| Sedation Scale | Clinical Response                                      |
|----------------|-------------------------------------------------------|
| 0              | Paralysed, Unable to evaluate                         |
| 1              | Awake                                                 |
| 2              | Lightly sedated                                      |
| 3              | Moderately sedated, follows simple commands           |
| 4              | Deeply sedated, responds to non-painful stimuli       |
| 5              | Deeply sedated, responds only to painful stimuli      |
| 6              | Deeply sedated, unresponsive to painful stimuli       |

3. DISCUSSION

We aim to reveal that the addition of intrathecal Nalbuphine 0.1ml(1mg) to 0.5% Bupivacaine 2.5 ml (12.5mg) improves the standard of the blockade and postop pain relief, improves hemodynamic stability & minimizes side effects in comparison to the addition of intrathecal midazolam 0.5ml (2.5mg)to 2.5 ml(12.5mg) of Hyperbaric(0.5%) Bupivacaine in cases of Total Abdominal Hysterectomy.

Fareed Ahmed et al. 2016 [12] deduced from their study that combining intrathecal bupivacaine & nalbuphine in cases of abdominal hysterectomy led to improvement of postoperative analgesia, in contrast to the control group. From the three doses of nalbuphine that were studied, 1.6mg of nalbuphine gave the best results.

T. Das et al. in 2017 [13], in their study for the relation between intrathecal nalbuphine and postoperative analgesia, found out that the addition of intrathecal nalbuphine leads to faster onset of sensorimotor block and slow regression of the block. Conversely, Tiwari et al in 2013 [14] found that adding intrathecal nalbuphine does not lead to any change in the onset of the sensorimotor blockade. These results were ascribed to the reduced dosing then in the study(0.2mg & 0.4mg), nalbuphine were used. In 2003 [15] in their study found out that midazolam increases the duration of motor blockade. Manisha Sapate et al. in 2013 [16] conducted a double-blinded, randomized control trial to find out the results of the addition of nalbuphine in abdominal surgeries under spinal anaesthesia (Bupivacaine). It was inferred that addition of nalbuphine improves the standard of block in contrast to views of bupivacaine alone. Further nalbuphine also extends postop pain relief in elderly patients. Several other studies were assessed [17-23].

4. LIMITATIONS

1. Drug given only by Intrathecal Route
2. This study will be limited to female patients undergoing total abdominal hysterectomy.
3. There is variation in pain threshold in between patients.

5. CONCLUSION

Adjuvant, Intrathecal Nalbuphine(1 mg), added to Hyperbaric Bupivacaine(12.5 mg) is expected to enhance the quality of block in comparison to (2.5 mg) Midazolam as an adjuvant to Bupivacaine. It is also expected for nalbuphine to provide 8-9 hours long postop analgesia when utilised in addition to bupivacaine, without producing noteworthy side effects in patients undergoing TAH under sub-arachnoid block.
CONSENT
As per international standard or university standard, patient’s written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL
As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS
Authors have declared that no competing interests exist.

REFERENCES
1. Brill R, MacFarlane AJR, Chan VW. Spinal, Epidural & Caudal Anaesthesia. In: Miller’s RD, Editor. Miller’s Anaesthesia. 8th edition Philadelphia: Saunders Elsevier. 2015; 1684-1720
2. Gomaa HM, Mohamed NM, Zoheir HH, Ali MS. A comparison between post-operative analgesia after intrathecal nalbuphine with bupivacaine & intrathecal fentanyl with bupivacaine after caesarean section. Eur J Anaesthesiology. 2014;30:405–410.
3. Heynick F, William T.G. Morton & The Great Moment. J Hist Dent. 2003; 51(1):27-35.
4. Kolawole IK, Bolaji BO. Subarachnoid block for lower abdominal & lower limb surgery: UITH experience. Niger J Med. 2002;11(4):153-5.
5. S.Swain A, Nag DS, Sahu S, Samaddar DP. Adjuvants to local anaesthetics: Current understanding & future trends. World J Clin Cases. 2017;5(8):307–323.
6. Engelmann E, Marsala C. Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: metaanalysis. Br J Anaesth. 2013;110:21–27.
7. Al-Mustafa MM, Abu-Halaweh SA, Aloweidi AS, Murshidi MM, Ammari BA, Awwad ZM, AlEdwan GM, Ramsay MA. Effect of Dexmedetomidine added to spinal Bupivacaine for urological procedures. Saudi Med J. 2009;30(3):365-70
8. Beaver WT, Feise GA. A comparison of analgesic effect of intramuscular nalbuphine & morphine in patients with postoperative pain. The Journal of Pharmacology & Experimental Therapeutics. 1978;204(2):487-496.
9. Reves JG et al.: Midazolam: Pharmacology & uses. Anaesthesiology. 1985;62:310-324.
10. Gerecke M: Chemical structure & properties of midazolam compared with other benzodiazepines. Br J Clin Pharmacol. 1983;16:115-16S.
11. Olfat Abdelmoniem, Dina Abdelhameed Elsaidek Salem. Nalbuphine versus midazolam as an adjuvant to intrathecal bupivacaine for postoperative analgesia in patients undergoing caesarean section. The Journal of Pain Research. 2020;13:1369-1376
12. Ahmed F, Narula H, Kh&elwal M, Dutta D. A comparative study of three different doses of nalbuphine as an adjuvant to intrathecal bupivacaine for postoperative analgesia in abdominal hysterectomy. Indian J Pain. 2016;30:23-8
13. Das T, Ray H, Baliairsingh P. A comparative study of efficacy of intrathecal nalbuphine in different doses as an adjuvant to levobupivacaine in subarachnoid block. Sch J Appl Med Sci. 2017;5(6E):2388–2392.
14. Tiwari AK, Tomar GS, Agrawal J. Intrathecal bupivacaine in comparison with a combination of nalbuphine & bupivacaine for subarachnoid block: a randomized prospective double – blind clinical study. Am J Ther. 2013; 20(6):592–595.
DOI:10.1097/MJT.0b013e31822048db
15. Bharti N, Madan R, Mohanty PR, et al. Intrathecal midazolam added to bupivacaine improves the duration & quality of spinal anaesthesia. Acta Anaesthesiol Sc &. 2003;47:1101–1105. DOI:10.1034/j.1399-6576.2003.00186.x
16. Sapate M, Sahu P, Thatte W.S, Dubey R. A randomized, double blind, control study of effects of adding nalbuphine to spinal bupivacaine for lower abdominal surgeries in elderly patients,Anaesth,Pain & Intensive Care. 2013;17(2).
17. Saadle Saad, Ehab E Alfi, El-Sayed M, Walid HI, Intrathecal bupivacaine as an adjuvant to bupivacaine in spinal anaesthesia for lower limb surgeries; intraoperative & postoperative effects January, Benha Medical Journal. 2018; 35(3):297.
18. Mukherjee A, Pal a, Agrawal J, Mehrotra A, Daraw N. Intrathecal nalbuphine as an adjuvant to subarachnoid block: What is the most effective dose? Anesth Essays Res. 2011;5:171-5.
19. DeSouza EB, Schmidt WK, Kuhar MJ. Nalbuphine: An auto radiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther 1988;244:391-402

20. Jyothi B, Shruthi Gowda, Safiya Shaikh. A comparison of analgesic effect of different doses of intrathecal nalbuphine hydrochloride with bupivacaine & bupivacaine alone for lower abdominal & orthopaedic surgeries. Indian J Pain 2014;28:18-23.

21. Dalal, Shivani Tejas, Sanjot Ninave. Postsurgical analgesic efficacy of epidural nalbuphine in lower abdominal surgeries. Journal of Evolution of Medical and Dental Sciences-Jemds 2020;9(4): 216–22. Available:https://doi.org/10.14260/jemds/2020/50.

22. Gantasala, Bhargav Vishnu, Amol Singam, Saranya Rallabhandi, Kashish Chaubey, Pallavi Deulkar, Ayush Pal Bansal. Comparison of Intrathecal Dexmedetomidine and Nalbuphine as an Adjuvant in Hyperbaric Bupivacaine for Saddle Block and Postoperative in Patients Perianal. Journal Of Evolution of Medical and Dental Sciences-Jemds. 2020;9(29):2028–33. Availalble:https://doi.org/10.14260/jemds/2020/442.

23. Shrey, Shruti, Amol Singam, Basant Singh Latwal, Pratibha Nagpure, and Ayushma. “A Comparative Study of Intraperitoneal Ropivacaine and Bupivacaine for Postoperative Analgesia in Laparoscopic Cholecystectomy.” Journal of Evolution of Medical And Dental Sciences-Jemds. 2020;9(4):200–205. Available:https://doi.org/10.14260/jemds/2020/47.